- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02671123
Does Co-registration of OCT and Angiography Reduce Geographic Miss of Stent Implantation?
Evaluation of Effect of Co-registration Between Optical Coherence Tomography (OCT) and Coronary Angiography Onto OCT Guided Percutaneous Coronary Intervention (PCI)
Study Overview
Status
Conditions
Detailed Description
Background: When a stent fails to fully cover the lesion, it is termed "geographic miss" (GM). Optical coherence tomography (OCT) is an intracoronary imaging modality that has higher resolution than conventional intracoronary ultrasound. Although OCT allows identification of the location of the culprit lesion and side branch using automated measures, it is sometimes difficult to identify the exact segment corresponding to angiography. Recently, co-registration of OCT and angiography has become available; however, whether this reduces the incidence of GM during stenting is unknown.
Hypothesis: OCT reduces GM during percutaneous coronary intervention.
Objectives:
- Determine the incidence of GM defined as residual disease* and significant edge dissection† at proximal and distal reference
- Determine the incidence of stent dislocation (distance between planned and actual stented place)
Determine procedural findings (additional stent, total fluoro time, total contrast volume)
Minimum lumen area <4.0 mm2 in the presence of significant residual plaque within 5 mm distal and proximal to the stent edge.
- A flap of vessel wall of >60° is seen in ≥2 consecutive cross-section image within 5 mm distal and proximal from stent edge Study Design and Methods: Single-center, prospective, randomized study. Consented subjects who are to undergo percutaneous coronary intervention are divided into 2 groups randomly (OCT with co-registration vs OCT without co-registration). After stent deployment guided by OCT, dissection, residual disease at the stent edge, and distance between planned and actual stent location are assessed using OCT or angiography. Additional stent deployment, procedure time, total fluoroscopy time, and total contrast volume are also evaluated.
Sample size considerations: OCT with co-registration: 100, OCT without co-registration: 100 (α=0.05, β =0.2). In a retrospective evaluation, the incidence of residual disease (lumen area <4.0 mm2 in the presence of significant residual plaque) or significant stent edge dissection was 36% (18/50, 34% [17/50] with residual stenosis, 4% [2/50] with significant edge dissection). Under the assumption that GM occurs in 36% of patients without co-registration and 18% of patients with co-registration, a group of 190 patients yields a power 80% (with a 2-sided α=0.05) to detect a difference in GM between patients with and without co-registration. In order to account for patient drop out and non-evaluable OCT recordings (5%), a total of 200 patients will be enrolled.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Richard A Shlofmitz, MD
- Phone Number: 516-390-9640
- Email: richard.shlofmitz@chsli.org
Study Contact Backup
- Name: Elizabeth S Haag, RN MPA
- Phone Number: 516 562-6790
- Email: elizabeth.haag@chsli.org
Study Locations
-
-
New York
-
Roslyn, New York, United States, 11576
- Recruiting
- St. Francis Hospital
-
Contact:
- Elizabeth S Haag, RN, MPA,CCRP
- Phone Number: 516-562-6790
- Email: elizabeth.haag@chsli.org
-
Contact:
- Lyn Santiago, RN,CCRC
- Phone Number: 516 562-6790
- Email: lyn.santiago@chsli.org
-
Principal Investigator:
- Richard A Shlofmitz, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
• Patients ≥18 years old who undergo percutaneous coronary intervention per clinical indications.
Exclusion Criteria:
- Left main disease
- Ostial lesion at Right Coronary Artery
- Tortuous artery in which OCT is unable to pass
- Lesion at bypass graft
- In-stent restenosis
- Chronic total occlusion
- Cardiogenic shock (sustained [>10 min] systolic blood pressure <90 mm Hg in absence of inotropic support or the presence of an intra-aortic balloon pump)
- Acute phase heart failure
- Sustained ventricular arrhythmias
- Known ejection fraction <35%
- Known severe valvular heart disease Known severe renal insufficiency (estimated glomerular filtration rate <30 mL/min/1.72 m2)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Coronary PCI with OCT with Co-Registration
Coronary stenting will be performed with OCT guidance as per local practice.
Pre and post stenting procedure will be performed with OCT guidance with the use of the Co-Registration software tool after stent implanted.
|
Co-Registration is an online tool used to take measurements during a stent procedure ( PCI-percutaneous coronary intervention) as part of the OCT ( Optical Coherence Tomography intravascular system.
Co Registration software may provide additional imaging details during stent implantation when using OCT.
|
Placebo Comparator: Coronary PCI with OCT without Co-Registration
Coronary stenting will be performed with OCT guidance as per local practice. Pre and post stenting procedure will be performed with OCT guidance without the use of the Co-Registration software tool after stent implanted. I |
Coronary PCI will be performed using OCT ( Optical Coherence Tomography intravascular system) guidance without the Co Registration software tool enabled.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Geographic miss
Time Frame: Intraoperative
|
Geographic miss defined as evidence of residual disease at stent edge or significant edge dissection after stent deployment
|
Intraoperative
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with Residual disease at stented edge
Time Frame: Intraoperative
|
Residual disease at stent edge will defined as minimum lumen area within 5mm from the stent edge evaluated by OCT.
This measurement will be analyzed by a core lab independently who will be blinded for randomization.
|
Intraoperative
|
Number of participants with stent edge dissection
Time Frame: peri procedure
|
Stent edge dissection will be defied as a flap of vessel wall and further categorized as intimal dissection, medial dissection, intramural hematoma, or extra-medial dissection.
Minimum lumen area, angle of dissection flap, and length of dissection will be measured by OCT by a core lab who is blinded to the randomization.
|
peri procedure
|
Distance between the planned and actual stent location
Time Frame: Intraoperative
|
Distance between the planned and actual stent location will be defined as the distance between the center of planned stent location and the center of actual stent location which will be recorded on the OCT software and analyzed by a core lab who is blinded to the randomization.
|
Intraoperative
|
Number of additional stents required
Time Frame: Intraoperative
|
This will be measured as number of participants with additional stent required.
|
Intraoperative
|
Procedure time
Time Frame: Intraoperative
|
time of PCI procedure defined as time vascular access obtained until guide catheter removed from access site.
|
Intraoperative
|
Total fluoroscopy time
Time Frame: intraoperative
|
total amount of fluoroscopy time used during procedure
|
intraoperative
|
Total contrast volume
Time Frame: intraoperative
|
total mount of contrast in ml used during entire PCI procedure
|
intraoperative
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Richard A Shlofmitz, MD, Chairman of Cardiology St Francis Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 16-02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on Coronary PCI with OCT with Co Registration
-
Erasmus Medical CenterRecruitingCoronary Artery Disease | Stable Angina | Percutaneous Coronary Intervention | Unstable Angina | Multi Vessel Coronary Artery Disease | Non-ST Elevation Myocardial Infarction | Optical Coherence TomographyNetherlands
-
Aarhus University Hospital SkejbyAbbottActive, not recruitingIschemic Heart Disease | Ischaemic Heart DiseaseDenmark, United Kingdom, Sweden, Finland, Germany, Belgium, Norway, Poland, Netherlands, Estonia, Ireland, Italy, Latvia
-
Philips Clinical & Medical Affairs GlobalCompletedCoronary Artery DiseaseIsrael, United States, Belgium, Spain
-
Abbott Medical DevicesAbbottCompletedCoronary Artery Disease | Atherosclerosis | Coronary Stenosis | STEMI | NSTEMI - Non-ST Segment Elevation MI | STEMI - ST Elevation Myocardial InfarctionUnited States, Spain, Australia, United Kingdom, Canada, New Zealand, Denmark, Switzerland, Germany, Netherlands, India, Japan, Italy, Belgium, France, Hong Kong, Portugal, Singapore, Sweden, Taiwan
-
Yonsei UniversityWithdrawnCoronary Bifurcation Lesions
-
Abbott Medical DevicesCardiovascular Research Foundation, New YorkCompletedCoronary Artery DiseaseUnited States, Spain, Japan, United Kingdom, Germany, Belgium, Italy, Netherlands
-
University National Heart HospitalRecruitingIschaemic Heart DiseaseBulgaria
-
Yonsei UniversityCompletedIschemic Heart DiseaseKorea, Republic of
-
University of PisaCompleted
-
University of Rome Tor VergataRecruitingCoronary Artery CalcificationItaly